

PharMerica CORP  
Form 8-K  
May 28, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2010

**PHARMERICA CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

001-33380  
(Commission  
File Number)  
1901 Campus Place

87-0792558  
(IRS Employer  
Identification No.)

Edgar Filing: PharMerica CORP - Form 8-K

**Louisville, Kentucky 40299**

**(Address of principal executive offices) (Zip Code)**

**(502) 627-7000**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The 2010 Annual Meeting of Stockholders of the Company was held on May 26, 2010. The following matters were voted upon and approved by the Company's stockholders at the meeting:

1. Election of nine directors for a term to expire at the Annual Meeting of Stockholders in 2011

| <b>Name</b>              | <b>For</b> | <b>Withheld Authority</b> | <b>Broker Non-Votes</b> |
|--------------------------|------------|---------------------------|-------------------------|
| Frank E. Collins, Esq.   | 27,199,452 | 25,694                    | 1,605,498               |
| W. Robert Dahl, Jr.      | 27,199,617 | 25,529                    | 1,605,498               |
| Marjorie W. Dorr         | 25,389,007 | 1,836,139                 | 1,605,498               |
| Thomas P. Gerrity, Ph.D. | 27,199,431 | 25,715                    | 1,605,498               |
| Thomas P. Mac Mahon      | 25,388,029 | 1,837,117                 | 1,605,498               |
| Daniel N. Mendelson      | 25,387,829 | 1,837,317                 | 1,605,498               |
| Geoffrey G. Meyers       | 27,198,435 | 26,711                    | 1,605,498               |
| Robert A. Oakley, Ph.D.  | 27,199,551 | 25,595                    | 1,605,498               |
| Gregory S. Weishar       | 27,198,599 | 26,547                    | 1,605,498               |

2. Approval of an amendment and restatement of the Company's Amended and Restated 2007 Omnibus Incentive Plan

| <b>For</b> | <b>Against</b> | <b>Abstained</b> | <b>Broker Non-Votes</b> |
|------------|----------------|------------------|-------------------------|
| 17,940,205 | 8,665,967      | 618,974          | 1,605,498               |

3. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2010

| <b>For</b> | <b>Against</b> | <b>Abstained</b> |
|------------|----------------|------------------|
| 28,715,550 | 111,484        | 3,610            |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMERICA CORPORATION

Date: May 27, 2010

By: /s/ Thomas Caneris  
Thomas Caneris  
Senior Vice President, General Counsel and Secretary